Company anticipates FDA approval of Jemperli in rectal cancer by February 2027.
Anaptys expects FDA approval of Quimilza in GPP in December 2026.
Company expects to achieve >$390 mln in annualized Jemperli royalties as early as 2029.
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$27.49 mln
Q2 Net Income
$183.88 mln
Q2 Income From Operations
$14.15 mln
Q2 Operating Expenses
$13.34 mln
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for AnaptysBio, Inc. is $85.50, about 54.9% above its September 18 closing price of $55.20.
Q2 results and revenue drivers
US royalty manager's Q2 collaboration revenue rose yr/yr, driven by higher Jemperli royalties.
ANAB•
